KR100694004B1 - 세포소멸을 유발시킬 수 있는 약제의 제조를 위한프로피오닐 ｌ-카르니틴의 용도 - Google Patents

세포소멸을 유발시킬 수 있는 약제의 제조를 위한프로피오닐 ｌ-카르니틴의 용도 Download PDF

Info

Publication number
KR100694004B1
KR100694004B1 KR1020017005575A KR20017005575A KR100694004B1 KR 100694004 B1 KR100694004 B1 KR 100694004B1 KR 1020017005575 A KR1020017005575 A KR 1020017005575A KR 20017005575 A KR20017005575 A KR 20017005575A KR 100694004 B1 KR100694004 B1 KR 100694004B1
Authority
KR
South Korea
Prior art keywords
carnitine
propionyl
plc
acid
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
KR1020017005575A
Other languages
English (en)
Korean (ko)
Other versions
KR20010080379A (ko
Inventor
칼바니메노티
피사노클라우디오
Original Assignee
시그마타우 인두스트리에 파르마슈티케 리우니테 에스.피.에이.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/IT1998/000318 external-priority patent/WO2000027386A1/en
Priority claimed from IT1998RM000701A external-priority patent/IT1302858B1/it
Application filed by 시그마타우 인두스트리에 파르마슈티케 리우니테 에스.피.에이. filed Critical 시그마타우 인두스트리에 파르마슈티케 리우니테 에스.피.에이.
Publication of KR20010080379A publication Critical patent/KR20010080379A/ko
Application granted granted Critical
Publication of KR100694004B1 publication Critical patent/KR100694004B1/ko
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/205—Amine addition salts of organic acids; Inner quaternary ammonium salts, e.g. betaine, carnitine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/221—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin with compounds having an amino group, e.g. acetylcholine, acetylcarnitine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Emergency Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
KR1020017005575A 1998-11-11 1999-11-09 세포소멸을 유발시킬 수 있는 약제의 제조를 위한프로피오닐 ｌ-카르니틴의 용도 Expired - Fee Related KR100694004B1 (ko)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
ITPCT/IT98/00318 1998-11-11
PCT/IT1998/000318 WO2000027386A1 (en) 1998-11-11 1998-11-11 Use of propionylcarnitine for the manufacture of a medicament for inhibiting smooth muscle cell proliferation
IT1998RM000701A IT1302858B1 (it) 1998-11-11 1998-11-11 Uso della l-carnitina e dei suoi alcanoil derivati per la preparazionedi un medicamento avente attivita' antitumorale.
ITRM98A000701 1998-11-11

Publications (2)

Publication Number Publication Date
KR20010080379A KR20010080379A (ko) 2001-08-22
KR100694004B1 true KR100694004B1 (ko) 2007-03-12

Family

ID=26330215

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020017005575A Expired - Fee Related KR100694004B1 (ko) 1998-11-11 1999-11-09 세포소멸을 유발시킬 수 있는 약제의 제조를 위한프로피오닐 ｌ-카르니틴의 용도

Country Status (6)

Country Link
EP (1) EP1128823A1 (enExample)
JP (1) JP2002529408A (enExample)
KR (1) KR100694004B1 (enExample)
AU (1) AU1294600A (enExample)
CA (1) CA2350071A1 (enExample)
WO (1) WO2000027387A1 (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101006207B1 (ko) * 2008-09-25 2011-01-07 김형호 잡음차단수단을 갖는 헤드셋

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997034596A1 (en) * 1996-03-15 1997-09-25 Mendes S.R.L. Use of an alkanoyl-l-carnitine for the treatment of glutamate mediated diseases

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1254314B (it) * 1992-03-27 1995-09-14 Sigma Tau Ind Farmaceuti Composizioni farmaceutiche conyenenti l-carnitina e acil- carnitine inassociazione con ace-inibitori per il trattamento di patologie cardiovascolari.
EP0681839A3 (en) * 1994-05-12 1997-11-12 Hirohiko Kuratsune A pharmaceutical preparation comprising an acylcarnitine
US5786326A (en) * 1995-02-03 1998-07-28 Horwitz; Lawrence D. Method for the treatment of atherosclerosis and vascular injury by prevention of vascular smooth muscle cell proliferation
IT1276253B1 (it) * 1995-12-15 1997-10-27 Sigma Tau Ind Farmaceuti Composizione farmaceutica contenente l-carnitina o alcanoil l-carnitine per la prevenzione ed il trattamento di stati morbosi
DK0793962T3 (da) * 1996-03-04 2000-05-22 Sigma Tau Ind Farmaceuti Lægemiddel indeholdende et carnitinderivat til behandling af arteriosclerosis obliterans

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997034596A1 (en) * 1996-03-15 1997-09-25 Mendes S.R.L. Use of an alkanoyl-l-carnitine for the treatment of glutamate mediated diseases

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Hypertension, 1996년, Vol. 28, pp. 177~182 *

Also Published As

Publication number Publication date
EP1128823A1 (en) 2001-09-05
KR20010080379A (ko) 2001-08-22
AU1294600A (en) 2000-05-29
CA2350071A1 (en) 2000-05-18
JP2002529408A (ja) 2002-09-10
WO2000027387A1 (en) 2000-05-18

Similar Documents

Publication Publication Date Title
Powell et al. The proliferative response to vascular injury is suppressed by angiotensin-converting enzyme inhibition
Soma et al. HMG CoA reductase inhibitors. In vivo effects on carotid intimal thickening in normocholesterolemic rabbits.
RU2597844C2 (ru) Введение гипоксически активируемых пролекарств и средств, препятствующих ангиогенезу, для лечения рака
Bauters et al. Mechanisms and prevention of restenosis: from experimental models to clinical practice
Malloy et al. Agents used in dyslipidemia
JP2005533810A (ja) 新規な抗コレステロール組成物及びその使用方法
HU215922B (hu) 1-[(4-Karbazolil)-oxi]-3-amino-2-propanol-származékok alkalmazása simaizomsejt-burjánzás gátlására szolgáló gyógyszerkészítmények előállítására
EA000190B1 (ru) Способы подавления миграции сосудистых гладкомышечных клеток
CN101801386A (zh) 抗血管生成剂和使用方法
JP2021046427A (ja) 炎症性腸疾患抑制剤
US5434185A (en) Method for inhibiting angiogenesis with aurintricarboxylic acid, its analogues or salts
UA73134C2 (en) Use of drugs possessing protective activity against oxidative-toxic effects of medicaments or chemicals, in particular cardiotoxic drugs
JP2019536783A (ja) チロシン誘導体及びそれらを含む組成物
CN1334738A (zh) 含有人参皂甙Rb1的脑血管再生/再造促进剂和继发性神经组织变性抑制剂
KR100694004B1 (ko) 세포소멸을 유발시킬 수 있는 약제의 제조를 위한프로피오닐 ｌ-카르니틴의 용도
KR20200005573A (ko) 암의 치료를 위한 약제학적 조합물
US20030220363A1 (en) Use of propionyl L-carnitine for the preparation of a medicament capable of inducing apoptosis
RU2358731C2 (ru) Cci-779 для лечения лимфомы из мантийных клеток
KR20010092751A (ko) 다발성 골수종의 골 병변 치료용 의약 조성물
KR19990087396A (ko) 재협착 치료 또는 예방용 의약의 제조를 위한 2-(3,4-디메톡시신남오일)아미노벤조산의 사용
Armstrong et al. Regression of atherosclerosis: A role for calcium antagonists
RU2339381C2 (ru) Ингибитор гиперплазии интимы сосудов
WO2000027386A1 (en) Use of propionylcarnitine for the manufacture of a medicament for inhibiting smooth muscle cell proliferation
US20180235936A1 (en) Cancer treatment methods
AU2002366975B2 (en) Quinazolinone compounds in combined modalities for improved cancer treatment

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

R17-X000 Change to representative recorded

St.27 status event code: A-3-3-R10-R17-oth-X000

A201 Request for examination
PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000

LAPS Lapse due to unpaid annual fee
PC1903 Unpaid annual fee

St.27 status event code: A-4-4-U10-U13-oth-PC1903

Not in force date: 20100307

Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

PC1903 Unpaid annual fee

St.27 status event code: N-4-6-H10-H13-oth-PC1903

Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

Not in force date: 20100307